Intellia Therapeutics Inc.
Organization details
- Legal name
- Intellia Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2835 — In Vitro & In Vivo Diagnostic Substances
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NTLA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001652130
- EIN
- 36-4785571
- Wikidata ID
- Q54621387
Board of directors
-
Brian Goff · DirectorSince 2024
-
Frank Verwiel · DirectorSince 2023
- Since 2023
-
Georgia Keresty · DirectorSince 2023
-
Jesse Goodman · DirectorSince 2023
-
John F. Crowley · DirectorSince 2023
-
John M. Leonard · Director · President and CEOSince 2023
-
Muna Bhanji · DirectorSince 2023
-
William J. Chase · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.6%
Board connections
8 of this board's directors also sit on 13 other boards. 12 are in the same sector.
-
Agios Pharmaceuticals Inc. Same sectorvia Brian Goff
-
Ardelyx Inc. Same sectorvia Muna Bhanji
-
CareDx Inc. Same sectorvia Fred E. Cohen
-
Cytokinetics Incorporated Same sectorvia Muna Bhanji
-
Entrada Therapeutics Inc. Same sectorvia John F. Crowley
-
GRAIL Inc. Same sectorvia William J. Chase
-
IQVIA Holdings Inc. Same sectorvia John M. Leonard
-
Kyverna Therapeutics Inc. Same sectorvia Fred E. Cohen
-
Progyny Inc. Same sectorvia Fred E. Cohen
-
Solid Biosciences Inc. Same sectorvia Georgia Keresty
- via Jesse Goodman
-
UroGen Pharma Ltd. Same sectorvia Fred E. Cohen
-
Veracyte Inc. Same sectorvia Muna Bhanji
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,402,500
- 1 purchase by 1 insider
- Sold, last 12 months
- $2,271,224
- 19 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | John M. Leonard Director, Officer (President and CEO) | Open-market sale | −9,000 | $11.99 | $107,910 |
| Oct 26, 2026 | Jing L. Marantz Officer (EVP, Chief Medical Officer) | Grant or award | +199,822 | — | — |
| Oct 2, 2026 | Dube Michael P Officer (VP, Chief Accounting Officer) | Open-market sale | −1,864 | $12.43 | $23,170 |
| Aug 21, 2026 | John M. Leonard Director, Officer (President and CEO) | Open-market sale | −2,785 | $13.00 | $36,205 |
| Aug 20, 2026 | John M. Leonard Director, Officer (President and CEO) | Open-market sale | −19,890 | $12.60 | $250,614 |
| Jul 22, 2026 | Dulac Edward J III Officer (EVP, Chief Financial Officer) | Open-market sale | −8,111 | $11.25 | $91,249 |
| Jul 2, 2026 | Dulac Edward J III Officer (EVP, Chief Financial Officer) | Open-market sale | −4,677 | $18.00 | $84,186 |
| Jul 1, 2026 | Dube Michael P Officer (VP, Chief Accounting Officer) | Open-market sale | −2,641 | $16.78 | $44,316 |
| Jun 9, 2026 | Frank Verwiel Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Georgia Keresty Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Jesse Goodman Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Brian Goff Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Fred E. Cohen Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | William J. Chase Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Muna Bhanji Director | Grant or award | +9,200 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Intellia Therapeutics Inc.
Who is the CEO of Intellia Therapeutics Inc.?
John M. Leonard is Intellia Therapeutics Inc.'s President and CEO.
How many directors are on Intellia Therapeutics Inc.'s board?
Intellia Therapeutics Inc.'s board has 9 directors: Brian Goff, Frank Verwiel, Fred E. Cohen, Georgia Keresty, Jesse Goodman, John F. Crowley, John M. Leonard, Muna Bhanji and William J. Chase.
Are Intellia Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Intellia Therapeutics Inc. insiders bought $1.4 million of shares in 1 purchase and sold $2.3 million of shares in 19 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="intellia-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.